[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"active-non-anterior-non-infectious-uveitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:active-non-anterior-non-infectious-uveitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100489343","phase-3-efficacy-and-tolerance-of-baricitinib-a-jak-inhibitor-in-the-treatment-of-refractory-non-infectious-non-anterior-uveitis-100489343",false,"NCT05651880","Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis","JAKUVEITE","Inclusion Criteria:\n\n* Patient with diagnosis of non-anterior non-infectious uveitis, refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab)\n* Need to stop biotherapy (anti-TNF alpha or tocilizumab) and conventional immunosuppressive drugs (mycofenolate mofetil, methotrexate, azathioprine, cyclosporine, interferon alpha 2a) for at least 10 days prior to the inclusion date\n\nExclusion Criteria:\n\n* 1\\. Isolated anterior uveitis. 2. Infectious uveitis. 3. Severe uveitis threatening the visual prognosis and requiring emergency treatment with intravenous corticosteroids.\n\n  4\\. Initial visual acuity \\> 1.3 LogMAR in at least one eye. 5. Corneal or lens opacity that prevents fundus visualization or may require cataract surgery during the study.\n\n  6\\. Contraindication to baricitinib (OLUMIANT 2 and 4 mg film-coated tablets) : Hypersensitivity to the active substance or to any of the excipients.\n\n  7\\. Contraindication to mydriasis. 8. Refractory glaucoma in either eye. 9. Monophthalmic patient. 10. Previous treatment with JAK inhibitors. 11. Intraocular corticosteroid injection (subconjunctival or laterobulbar) within 1 month prior to inclusion or intravitreal corticosteroid implant within 3 months prior to inclusion.\n\n  12\\. Need for treatment with a biotherapy (anti-IL6, anti-IL6 receptor, anti-IL1, anti-IL12\u002FIL23 anti-IL17, anti-BAFF) for extra-ocular involvement, during the entire study period.\n\n  13\\. Treatment with OAT3 inhibitors with high inhibitory potential such as probenecid, leflunomide, teriflunomide 14. 14. Vaccination with a live or live attenuated vaccine within 15 days prior to inclusion 15. History of cancer within the previous 5 years, except non-metastatic squamous cell and basal cell carcinoma of the skin.\n\n  16\\. Personal history of venous thromboembolic disease.","ALL","18 Years","75 Years",{"count":20,"type":21},33,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The aim of the study is to evaluate the efficacy of Baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab) after 6 months of treatment",[27],"Active Non-anterior Non-infectious Uveitis","NOT_YET_RECRUITING","2026-06-05",{"date":31,"type":32},"2026-06-08","ACTUAL",{"date":34,"type":21},"2026-07",{"date":36,"type":21},"2029-12",{"name":38,"class":39},"University Hospital, Rouen","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":40},"100635386","phase-2-a-phase-ii-clinical-trial-to-evaluate-the-efficacy-and-safety-of-fxs5626-in-patients-with-niu-100635386","NCT07552012","A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of FXS5626 Tablets in Patients With Active Non-infectious Uveitis","Inclusion Criteria:\n\n1. Participants must be capable of understanding the trial procedures, voluntarily agree to participate, communicate effectively with the investigators, comply with all study requirements throughout the trial, and provide written Informed consent Form (ICF);\n2. At screening visit, male or female paticipants aged 18-70 years (inclusive) ;\n3. At screening visit, Body mass index (BMI) between 18 and 30 kg\u002Fm² (inclusive), with a body weight of ≥50 kg for males and ≥45 kg for females;\n4. At screening, at least one eye was diagnosed with active non-infectious uveitis by the investigator, including non-infectious intermediate uveitis, posterior uveitis, or panuveitis;\n5. Subject must have active disease at the screening and baseline visit, as defined by the presence of at least 1 of the following parameters in at least one eye despite at least 2 weeks of maintenance therapy with oral prednisone ≥ 10 mg\u002Fday to ≤ 60 mg\u002Fday (or oral corticosteroid equivalent):\n\n1\\) Active, inflammatory, chorioretinal and\u002For inflammatory retinal vascular lesion 2) ≥ 2+ anterior chamber cells (Standardization of Uveitis Nomenclature \\[SUN\\] criteria) 3) ≥ 2+ vitreous haze (National Eye Institute \\[NEI\\]\u002FSUN criteria) ; \\[6\\] Participants and their partners must have no plans for reproduction, sperm donation, or egg donation from the start of treatment until at least one month after the last dose of the investigational drug, and must voluntarily employ an effective method of contraception as determined by the investigator.\n\nExclusion Criteria:\n\n1. Participants with isolated anterior uveitis;\n2. Participants with macular edema as the sole clinical manifestation of intermediate uveitis, posterior uveitis, or panuveitis;\n3. Participants with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to Tuberculosis (TB), cytomegalovirus (CMV), Lyme disease, toxoplasmosis, Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease and herpes simplex virus (HSV);\n4. Participants with Histoplasmosis Syndrome (HS);\n5. Participants with ocular masquerade syndrome, including but not limited to the following causes: trauma, lymphoma, ocular malignant tumor, or surgery;\n6. Participants with serpiginous choroidopathy;\n7. Participants with corneal or lens opacity that precludes visualization of the fundus in either eye or that likely requires cataract surgery during the duration of the trial;\n8. Participants with severe vitreous opacity or other factors that precludes visualization of the fundus in either eye;\n9. Participant with uncontrolled glaucoma, intraocular pressure of ≥ 25 mmHg and on ≥ 2 glaucoma medications or evidence of glaucomatous optic nerve injury; The sponsor provides the definitive and complete eligibility criteria in the study protocol.","70 Years",{"count":50,"type":21},40,[52],"PHASE2","The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).",[55],"Active Non-anterior, Non-infectious Uveitis",[57,58,59,60],"Uveitis","Active","Non-anterior","Non-infectious","RECRUITING","2026-04-20",{"date":64,"type":32},"2026-04-27",{"date":66,"type":32},"2026-01-29",{"date":68,"type":21},"2027-12-31",{"name":70,"class":71},"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","INDUSTRY"]